Alfredo G Torres

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/693680/publications.pdf

Version: 2024-02-01

160 papers	9,230 citations	50276 46 h-index	46799 89 g-index
170 all docs	170 docs citations	170 times ranked	7852 citing authors

#	Article	IF	Citations
1	Optimization of Multivalent Gold Nanoparticle Vaccines Eliciting Humoral and Cellular Immunity in an In Vivo Model of Enterohemorrhagic Escherichia coli O157:H7 Colonization. MSphere, 2022, 7, e0093421.	2.9	5
2	SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses, 2022, 14, 653.	3.3	39
3	The Challenge to Control Emergence of Antibiotic Resistance in Virulent Escherichia coli Isolates in Latin America. Microbiology Spectrum, 2022, 10, .	3.0	2
4	Development of Melioidosis Subunit Vaccines Using an Enzymatically Inactive Burkholderia pseudomallei AhpC. Infection and Immunity, 2022, 90, .	2.2	7
5	Genomic Diversity of Burkholderia pseudomallei Isolates, Colombia. Emerging Infectious Diseases, 2021, 27, 655-658.	4.3	4
6	Description of two fatal cases of melioidosis in Mexican children with acute pneumonia: case report. BMC Infectious Diseases, 2021, 21, 204.	2.9	7
7	Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia Î”tonB Î”hcp1 live attenuated vaccines. Npj Vaccines, 2021, 6, 72.	6.0	12
8	Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed T _H 1-T _H 17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei. MBio, 2021, 12, e0122721.	4.1	18
9	Why Do We Need To Diversify the Microbial Sciences?. MSphere, 2021, 6, e0062521.	2.9	1
10	Recent Progress in Shigella and Burkholderia pseudomallei Vaccines. Pathogens, 2021, 10, 1353.	2.8	3
11	Diversity, Equity, and Inclusion in the Microbial Sciencesâ€"the Texas Perspective. MBio, 2021, 12, e0262021.	4.1	1
12	Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance. Pharmaceutics, 2021, 13, 1965.	4.5	6
13	Comparative genomics of a subset of Adherent/Invasive Escherichia coli strains isolated from individuals without inflammatory bowel disease. Genomics, 2020, 112, 1813-1820.	2.9	16
14	Combating the great mimicker: latest progress in the development of Burkholderia pseudomallei vaccines. Expert Review of Vaccines, 2020, 19, 653-660.	4.4	11
15	Predicting toxins found in toxinâ€"antitoxin systems with a role in host-induced Burkholderia pseudomallei persistence. Scientific Reports, 2020, 10, 16923.	3.3	6
16	Burkholderia pseudomallei as an Enteric Pathogen: Identification of Virulence Factors Mediating Gastrointestinal Infection. Infection and Immunity, 2020, 89, .	2.2	11
17	Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against Burkholderia mallei. Npj Vaccines, 2020, 5, 82.	6.0	20
18	Multinucleated Giant Cell Formation as a Portal to Chronic Bacterial Infections. Microorganisms, 2020, 8, 1637.	3.6	14

#	Article	IF	Citations
19	Hacking the host: exploitation of macrophage polarization by intracellular bacterial pathogens. Pathogens and Disease, 2020, 78, .	2.0	50
20	Vacunas contra el SARS-CoV-2: Â¿son una realidad para AmÃ©rica Latina?. Biomedica, 2020, 40, 424-426.	0.7	3
21	Evaluating the role of Burkholderia pseudomallei K96243 toxins BPSS0390, BPSS0395, and BPSS1584 in persistent infection. Cellular Microbiology, 2019, 21, e13096.	2.1	15
22	Evaluation of Burkholderia mallei Î”tonB Î”hcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis. PLoS Neglected Tropical Diseases, 2019, 13, e0007578.	3.0	16
23	Emerging role of biologics for the treatment of melioidosis and glanders. Expert Opinion on Biological Therapy, 2019, 19, 1319-1332.	3.1	8
24	Development of a Gold Nanoparticle Vaccine against Enterohemorrhagic Escherichia coli O157:H7. MBio, 2019, 10, .	4.1	42
25	Burkholderia mallei and Glanders. , 2019, , 161-183.		4
26	Melioidosis in Mexico: a Coordinated Effort to Educate the Medical Specialists and the Community About an Unknown Disease Endemic in the Country. Current Tropical Medicine Reports, 2019, 6, 116-119.	3.7	1
27	Melioidosis: The hazards of incomplete peer-review. PLoS Neglected Tropical Diseases, 2019, 13, e0007123.	3.0	1
28	Misidentification of Burkholderia pseudomallei and Other Burkholderia Species From Pediatric Infections in Mexico. Open Forum Infectious Diseases, 2019, 6, ofz008.	0.9	8
29	Novel multi-component vaccine approaches for Burkholderia pseudomallei. Clinical and Experimental Immunology, 2019, 196, 178-188.	2.6	28
30	Burkholderia pseudomallei Î” tonB Î” hcp1 Live Attenuated Vaccine Strain Elicits Full Protective Immunity against Aerosolized Melioidosis Infection. MSphere, 2019, 4, .	2.9	41
31	Increased Mortality in Mice following Immunoprophylaxis Therapy with High Dosage of Nicotinamide in Burkholderia Persistent Infections. Infection and Immunity, 2019, 87, .	2.2	6
32	Melioidosis. Nature Reviews Disease Primers, 2018, 4, 17107.	30.5	430
33	Development of Subunit Vaccines That Provide High-Level Protection and Sterilizing Immunity against Acute Inhalational Melioidosis. Infection and Immunity, 2018, 86, .	2.2	55
34	Recent Advances in Shiga Toxin-Producing Escherichia coli Research in Latin America. Microorganisms, 2018, 6, 100.	3.6	41
35	Melioidosis in Mexico, Central America, and the Caribbean. Tropical Medicine and Infectious Disease, 2018, 3, 24.	2.3	31
36	Evaluating New Compounds to Treat Burkholderia pseudomallei Infections. Frontiers in Cellular and Infection Microbiology, 2018, 8, 210.	3.9	29

#	Article	IF	Citations
37	Escherichia coli diseases in Latin Americaâ€"a â€˜One Healthâ€™ multidisciplinary approach. Pathogens and Disease, 2017, 75, .	2.0	32
38	Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei. Vaccine Journal, 2017, 24, .	3.1	46
39	Maternal immunity, a way to confer protection against enteropathogenic Escherichia coli. Jornal De Pediatria (VersÃ£o Em PortuguÃªs), 2017, 93, 548-550.	0.2	0
40	Characterization of the Burkholderia cenocepacia TonB Mutant as a Potential Live Attenuated Vaccine. Vaccines, 2017, 5, 33.	4.4	13
41	Comparing in vitro and in vivo virulence phenotypes of Burkholderia pseudomallei type G strains. PLoS ONE, 2017, 12, e0175983.	2.5	5
42	The Importance of International Collaborations to Advance Research Endeavors. PLoS Pathogens, 2017, 13, e1006047.	4.7	5
43	Burkholderia cepacia Complex Vaccines: Where Do We Go from here?. Vaccines, 2016, 4, 10.	4.4	20
44	From In silico Protein Epitope Density Prediction to Testing Escherichia coli O157:H7 Vaccine Candidates in a Murine Model of Colonization. Frontiers in Cellular and Infection Microbiology, 2016, 6, 94.	3.9	12
45	Polysorbates prevent biofilm formation and pathogenesis of Escherichia coli O104:H4. Biofouling, 2016, 32, 1131-1140.	2.2	20
46	Characterization of the universal stress protein F from atypical enteropathogenic Escherichia coli and its prevalence in Enterobacteriaceae. Protein Science, 2016, 25, 2142-2151.	7.6	17
47	The art of persistenceâ€"the secrets toBurkholderiachronic infections. Pathogens and Disease, 2016, 74, ftw070.	2.0	33
48	Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders. Infection and Immunity, 2016, 84, 2345-2354.	2.2	27
49	Melioidosis: where do we stand in the development of an effective vaccine?. Future Microbiology, 2016, 11, 477-480.	2.0	7
50	The Escherichia coli O157:H7 cattle immunoproteome includes outer membrane protein A (OmpA), a modulator of adherence to bovine rectoanal junction squamous epithelial (RSE) cells. Proteomics, 2015, 15, 1829-1842.	2.2	15
51	Consensus on the Development of Vaccines against Naturally Acquired Melioidosis. Emerging Infectious Diseases, 2015, 21, .	4.3	57
52	Long polar fimbriae participates in the induction of neutrophils transepithelial migration across intestinal cells infected with enterohemorrhagic E. coli O157:H7. Frontiers in Cellular and Infection Microbiology, 2015, 4, 185.	3.9	11
53	Extensive Identification of Bacterial Riboflavin Transporters and Their Distribution across Bacterial Species. PLoS ONE, 2015, 10, e0126124.	2.5	98
54	The Role of Long Polar Fimbriae in Escherichia coli O104:H4 Adhesion and Colonization. PLoS ONE, 2015, 10, e0141845.	2.5	30

#	Article	IF	Citations
55	Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine, 2015, 33, 686-692.	3.8	59
56	A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 447-456.	3.3	79
57	Enteropathogenic Escherichia coli: foe or innocent bystander?. Clinical Microbiology and Infection, 2015, 21, 729-734.	6.0	147
58	The IbeA Invasin of Adherent-Invasive Escherichia coli Mediates Interaction with Intestinal Epithelia and Macrophages. Infection and Immunity, 2015, 83, 1904-1918.	2.2	65
59	Recent Advances in Burkholderia mallei and B. pseudomallei Research. Current Tropical Medicine Reports, 2015, 2, 62-69.	3.7	41
60	Finding Regulators Associated with the Expression of the Long Polar Fimbriae in Enteropathogenic Escherichia coli. Journal of Bacteriology, 2015, 197, 3658-3665.	2.2	2
61	Characterization of the Burkholderia mallei tonB Mutant and Its Potential as a Backbone Strain for Vaccine Development. PLoS Neglected Tropical Diseases, 2015, 9, e0003863.	3.0	36
62	Exploiting the power of OMICS approaches to produceE. coliO157 vaccines. Gut Microbes, 2014, 5, 770-774.	9.8	8
63	Environmental regulation of the long polar fimbriae 2 of enterohemorrhagicEscherichia coliO157:H7. FEMS Microbiology Letters, 2014, 357, n/a-n/a.	1.8	12
64	Recent advances in adherence and invasion of pathogenic Escherichia coli. Current Opinion in Infectious Diseases, 2014, 27, 459-464.	3.1	78
65	A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Protection against Lethal Sepsis. Vaccine Journal, 2014, 21, 747-754.	3.1	85
66	Comparative Genomics and Immunoinformatics Approach for the Identification of Vaccine Candidates for Enterohemorrhagic Escherichia coli O157:H7. Infection and Immunity, 2014, 82, 2016-2026.	2.2	30
67	Enterohemorrhagic Escherichia coli Adhesins. Microbiology Spectrum, 2014, 2, EHEC00032013.	3.0	109
68	Comparative Burkholderia pseudomallei natural history virulence studies using an aerosol murine model of infection. Scientific Reports, 2014, 4, 4305.	3.3	43
69	Identification and Characterization of RibN, a Novel Family of Riboflavin Transporters from Rhizobium leguminosarum and Other Proteobacteria. Journal of Bacteriology, 2013, 195, 4611-4619.	2.2	33
70	Hybrid and potentially pathogenic Escherichia coli strains. , 2013, , 331-359.		0
71	The long polar fimbriae of STEC O157:H7 induce expression of pro-inflammatory markers by intestinal epithelial cells. Veterinary Immunology and Immunopathology, 2013, 152, 126-131.	1.2	18
72	Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection. Vaccine, 2013, 31, 3229-3235.	3.8	46

#	Article	IF	Citations
73	Restrictive Streptomycin Resistance Mutations Decrease the Formation of Attaching and Effacing Lesions in Escherichia coli O157:H7 Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 4260-4266.	3.2	5
74	The long polar fimbriae operon and its flanking regions in bovineEscherichia coliO157:H43 and STEC O136:H12 strains. Pathogens and Disease, 2013, 68, 1-7.	2.0	2
75	Monitoring Therapeutic Treatments against Burkholderia Infections Using Imaging Techniques. Pathogens, 2013, 2, 383-401.	2.8	10
76	Molecular Mechanisms That Mediate Colonization of Shiga Toxin-Producing Escherichia coli Strains. Infection and Immunity, 2012, 80, 903-913.	2.2	141
77	Identification of Coli Surface Antigen 23, a Novel Adhesin of Enterotoxigenic Escherichia coli. Infection and Immunity, 2012, 80, 2791-2801.	2.2	42
78	Development of a Multiplex PCR Assay for Detection of Shiga Toxin-Producing Escherichia coli, Enterohemorrhagic E. coli, and Enteropathogenic E. coli Strains. Frontiers in Cellular and Infection Microbiology, 2012, 2, 8.	3.9	39
79	A Double, Long Polar Fimbria Mutant of Escherichia coli O157:H7 Expresses Curli and Exhibits Reduced In Vivo Colonization. Infection and Immunity, 2012, 80, 914-920.	2.2	50
80	In vivo bioluminescence imaging of Escherichia coli O104:H4 and role of aerobactin during colonization of a mouse model of infection. BMC Microbiology, 2012, 12, 112.	3.3	19
81	Fimbriation and curliation in Escherichia coli O157. Gut Microbes, 2012, 3, 272-276.	9.8	37
82	Clinical Implications of Enteroadherent Escherichia coli. Current Gastroenterology Reports, 2012, 14, 386-394.	2.5	28
83	Immunomodulation for gastrointestinal infections. Expert Review of Anti-Infective Therapy, 2012, 10, 391-400.	4.4	30
84	Recent Progress in Melioidosis and Glanders. Frontiers in Microbiology, 2012, 3, 149.	3.5	4
85	Prophylactic Application of CpG Oligonucleotides Augments the Early Host Response and Confers Protection in Acute Melioidosis. PLoS ONE, 2012, 7, e34176.	2.5	25
86	Polysaccharide Specific Monoclonal Antibodies Provide Passive Protection against Intranasal Challenge with Burkholderia pseudomallei. PLoS ONE, 2012, 7, e35386.	2.5	42
87	Roles and Specificities of LPS from Highly Pathogenic Burkholderia Species. FASEB Journal, 2012, 26, 991.7.	0.5	0
88	Development of reagents and assays for the detection of pathogenic Burkholderia species. Faraday Discussions, 2011, 149, 23-36.	3.2	4
89	Host S-nitrosylation inhibits clostridial small moleculeâ€“activated glucosylating toxins. Nature Medicine, 2011, 17, 1136-1141.	30.7	75
90	In vivo bioluminescence imaging of Burkholderia mallei respiratory infection and treatment in the mouse model. Frontiers in Microbiology, 2011, 2, 174.	3.5	38

#	Article	IF	Citations
91	Protective Antigens Against Glanders Identified by Expression Library Immunization. Frontiers in Microbiology, 2011, 2, 227.	3.5	16
92	Adhesin-Encoding Genes from Shiga Toxin-Producing Escherichia coli Are More Prevalent in Atypical than in Typical Enteropathogenic E. coli. Journal of Clinical Microbiology, 2011, 49, 3334-3337.	3.9	26
93	Regulatory Control of the Escherichia coli O157:H7 lpf1 Operon by H-NS and Ler. Journal of Bacteriology, 2011, 193, 1622-1632.	2.2	23
94	Long Polar Fimbriae of Enterohemorrhagic Escherichia coli O157:H7 Bind to Extracellular Matrix Proteins. Infection and Immunity, 2011, 79, 3744-3750.	2.2	63
95	Escherichia coli-Related Diseases in Latin America Remain in the Spotlight: the Brazilian Efforts to Understand E. coli Pathogenesis. Open Microbiology Journal, 2011, 5, 54-54.	0.7	1
96	Genome sequence of adherent-invasive Escherichia coli and comparative genomic analysis with other E. coli pathotypes. BMC Genomics, 2010, 11, 667.	2.8	193
97	Identification of the long polar fimbriae gene variants in the locus of enterocyte effacement-negative Shiga toxin-producing â€ƒEscherichia coliâ€ƒstrains isolated from humans and cattle in Argentina. FEMS Microbiology Letters, 2010, 308, no-no.	1.8	14
98	Testing the Efficacy and Toxicity of Adenylyl Cyclase Inhibitors against Enteric Pathogens Using In Vitro and In Vivo Models of Infection. Infection and Immunity, 2010, 78, 1740-1749.	2.2	12
99	A transcriptome study of the QseEF two-component system and the QseG membrane protein in enterohaemorrhagic Escherichia coli O157â€Š:â€ŠH7. Microbiology (United Kingdom), 2010, 156, 1167-1175.	1.8	26
100	Outbreak Caused bycad-Negative Shiga Toxinâ€“ProducingEscherichia coliO111, Oklahoma. Foodborne Pathogens and Disease, 2010, 7, 107-109.	1.8	14
101	Present and future therapeutic strategies for melioidosis and glanders. Expert Review of Anti-Infective Therapy, 2010, 8, 325-338.	4.4	91
102	Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge. Procedia in Vaccinology, 2010, 2, 73-77.	0.4	38
103	Genes Related to Long Polar Fimbriae of Pathogenic Escherichia coli Strains as Reliable Markers To Identify Virulent Isolates. Journal of Clinical Microbiology, 2009, 47, 2442-2451.	3.9	48
104	The two-component system QseEF and the membrane protein QseG link adrenergic and stress sensing to bacterial pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5889-5894.	7.1	137
105	Burkholderia mallei cellular interactions in a respiratory cell model. Journal of Medical Microbiology, 2009, 58, 554-562.	1.8	30
106	Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin. BMC Microbiology, 2009, 9, 88.	3.3	18
107	The cad locus of Enterobacteriaceae: More than just lysine decarboxylation. Anaerobe, 2009, 15, 1-6.	2.1	26
108	Synthesis and in vitro Efficacy Studies of Silver Carbene Complexes on Biosafety Level 3 Bacteria. European Journal of Inorganic Chemistry, 2009, 2009, 1739-1745.	2.0	61

#	Article	IF	Citations
109	Intestinal Pathogenic Escherichia coli. , 2009, , 1013-1029.		4
110	Molecular Approaches to Bacterial Vaccines. , 2009, , 63-76.		4
111	Comparative Antimicrobial Activity of Granulysin against Bacterial Biothreat Agents. Open Microbiology Journal, 2009, 3, 92-96.	0.7	17
112	Sero-characterization of lipopolysaccharide from Burkholderia thailandensis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, S58-S60.	1.8	15
113	Construction of a reporter system to study Burkholderia mallei type III secretion and identification of the BopA effector protein function in intracellular survival. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, S127-S133.	1.8	15
114	The effects of lowâ€shear stress on Adherentâ€invasive Escherichia coli. Environmental Microbiology, 2008, 10, 1512-1525.	3.8	44
115	Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei. BMC Immunology, 2008, 9, 55.	2.2	23
116	Escherichia coli isolated from a Crohn's disease patient adheres, invades, and induces inflammatory responses in polarized intestinal epithelial cells. International Journal of Medical Microbiology, 2008, 298, 397-409.	3.6	163
117	Polysaccharides Cellulose, Poly-Î²-1,6- N -Acetyl- <scp>d</scp> -Glucosamine, and Colanic Acid Are Required for Optimal Binding of Escherichia coli O157:H7 Strains to Alfalfa Sprouts and K-12 Strains to Plastic but Not for Binding to Epithelial Cells. Applied and Environmental Microbiology, 2008, 74, 2384-2390.	3.1	92
118	Subtractive hybridization and identification of putative adhesins in a Shiga toxin-producing eae-negative Escherichia coli. Microbiology (United Kingdom), 2008, 154, 3639-3648.	1.8	8
119	Contribution of the Ler- and H-NS-Regulated Long Polar Fimbriae of Escherichia coli O157:H7 during Binding to Tissue-Cultured Cells. Infection and Immunity, 2008, 76, 5062-5071.	2.2	32
120	CadA Negatively Regulates Escherichia coli O157:H7 Adherence and Intestinal Colonization. Infection and Immunity, 2008, 76, 5072-5081.	2.2	29
121	Host-Microbe Communication within the GI Tract. Advances in Experimental Medicine and Biology, 2008, 635, 93-101.	1.6	23
122	A Novel Two-Component Signaling System That Activates Transcription of an Enterohemorrhagic Escherichia coli Effector Involved in Remodeling of Host Actin. Journal of Bacteriology, 2007, 189, 2468-2476.	2.2	127
123	Environmental regulation and colonization attributes of the long polar fimbriae (LPF) of Escherichia coli O157:H7. International Journal of Medical Microbiology, 2007, 297, 177-185.	3.6	54
124	Ler and H-NS, Regulators Controlling Expression of the Long Polar Fimbriae of Escherichia coli O157:H7. Journal of Bacteriology, 2007, 189, 5916-5928.	2.2	59
125	Bile salts induce expression of the afimbrial LDA adhesin of atypical enteropathogenic Escherichia coli. Cellular Microbiology, 2007, 9, 1039-1049.	2.1	21
126	Glanders: off to the races with Burkholderia mallei. FEMS Microbiology Letters, 2007, 277, 115-122.	1.8	149

#	Article	IF	Citations
127	Identification and characterization of â€œpathoadaptive mutationsâ€•of the cadBA operon in several intestinal Escherichia coli. International Journal of Medical Microbiology, 2006, 296, 547-552.	3.6	17
128	Adhesins of Enteropathogenic Escherichia coli. EcoSal Plus, 2006, 2, .	5.4	3
129	Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cellular Microbiology, 2006, 8, 869-879.	2.1	82
130	Long polar fimbriae and tissue tropism in Escherichia coli O157:H7. Microbes and Infection, 2006, 8, 1741-1749.	1.9	43
131	Outer Membrane Protein A of Escherichia coli O157:H7 Stimulates Dendritic Cell Activation. Infection and Immunity, 2006, 74, 2676-2685.	2.2	64
132	The lpf Gene Cluster for Long Polar Fimbriae Is Not Involved in Adherence of Enteropathogenic Escherichia coli or Virulence of Citrobacter rodentium. Infection and Immunity, 2006, 74, 265-272.	2.2	28
133	Cloning, Expression, and Characterization of Fimbrial Operon F9 from Enterohemorrhagic Escherichia coli O157:H7. Infection and Immunity, 2006, 74, 2233-2244.	2.2	89
134	Identification and Characterization of the Locus for Diffuse Adherence, Which Encodes a Novel Afimbrial Adhesin Found in Atypical Enteropathogenic Escherichia coli. Infection and Immunity, 2005, 73, 4753-4765.	2.2	40
135	Differential Binding of Escherichia coli O157:H7 to Alfalfa, Human Epithelial Cells, and Plastic Is Mediated by a Variety of Surface Structures. Applied and Environmental Microbiology, 2005, 71, 8008-8015.	3.1	103
136	Adherence of Diarrheagenic Escherichia coli Strains to Epithelial Cells. Infection and Immunity, 2005, 73, 18-29.	2.2	195
137	Pathoadaptive Mutation That Mediates Adherence of Shiga Toxin-Producing Escherichia coli O111. Infection and Immunity, 2005, 73, 4766-4776.	2.2	34
138	Molecular Epidemiology of the Iron Utilization Genes of Enteroaggregative Escherichia coli. Journal of Clinical Microbiology, 2004, 42, 36-44.	3.9	53
139	Long Polar Fimbriae Contribute to Colonization by Escherichia coli O157:H7 In Vivo. Infection and Immunity, 2004, 72, 6168-6171.	2.2	92
140	Characterization of the second long polar (LP) fimbriae ofEscherichia coliO157:H7 and distribution of LP fimbriae in other pathogenicE. colistrains. FEMS Microbiology Letters, 2004, 238, 333-344.	1.8	75
141	Characterization of the second long polar (LP) fimbriae of O157:H7 and distribution of LP fimbriae in other pathogenic strains. FEMS Microbiology Letters, 2004, 238, 333-344.	1.8	93
142	Current aspects of Shigella pathogenesis. Revista Latinoamericana De MicrobiologÃa, 2004, 46, 89-97.	0.1	19
143	Flagellin of Enteropathogenic Escherichia coli Stimulates Interleukin-8 Production in T84 Cells. Infection and Immunity, 2003, 71, 2120-2129.	2.2	125
144	Bacteriaâ€“host communication: The language of hormones. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8951-8956.	7.1	776

#	Article	IF	Citations
145	Multiple Elements Controlling Adherence of Enterohemorrhagic Escherichia coli O157:H7 to HeLa Cells. Infection and Immunity, 2003, 71, 4985-4995.	2.2	160
146	Identification and Characterization of lpfABCC â€² DE , a Fimbrial Operon of Enterohemorrhagic Escherichia coli O157:H7. Infection and Immunity, 2002, 70, 5416-5427.	2.2	173
147	Quorum sensingEscherichia coliregulators B and C (QseBC): a novel two-component regulatory system involved in the regulation of flagella and motility by quorum sensing inE. coli. Molecular Microbiology, 2002, 43, 809-821.	2.5	457
148	The flagella of enteropathogenic Escherichia coli mediate adherence to epithelial cells. Molecular Microbiology, 2002, 44, 361-379.	2.5	334
149	StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. Molecular Microbiology, 2002, 45, 277-288.	2.5	158
150	Characterization of Cah, a calcium-binding and heat-extractable autotransporter protein of enterohaemorrhagic Escherichia coli. Molecular Microbiology, 2002, 45, 951-966.	2.5	100
151	Quorum Sensing Is a Global Regulatory Mechanism in Enterohemorrhagic Escherichia coli O157:H7. Journal of Bacteriology, 2001, 183, 5187-5197.	2.2	389
152	TonB-Dependent Systems of Uropathogenic Escherichia coli : Aerobactin and Heme Transport and TonB Are Required for Virulence in the Mouse. Infection and Immunity, 2001, 69, 6179-6185.	2.2	267
153	TonB Is Required for Intracellular Growth and Virulence of Shigella dysenteriae. Infection and Immunity, 2000, 68, 6329-6336.	2.2	43
154	TonB Is Required for Intracellular Growth and Virulence of Shigella dysenteriae. Infection and Immunity, 2000, 68, 6329-6336.	2.2	6
155	The aerobactin iron transport system genes in Shigella flexneri are present within a pathogenicity island. Molecular Microbiology, 1999, 33, 63-73.	2.5	135
156	Structure of the Shigella dysenteriae haem transport locus and its phylogenetic distribution in enteric bacteria. Molecular Microbiology, 1998, 28, 1139-1152.	2.5	137
157	Haem ironâ€transport system in enterohaemorrhagic Escherichia coli O157:H7. Molecular Microbiology, 1997, 23, 825-833.	2.5	230
158	TolC and DsbA are needed for the secretion of STB, a heat-stable enterotoxin ofEscherichia coli. Molecular Microbiology, 1995, 18, 237-245.	2.5	53
159	Enterohemorrhagic Escherichia coli Adhesins. , 0, , 131-155.		2
160	Evaluating the Contribution of the Predicted Toxinâ€“Antitoxin System HigBA to Persistence, Biofilm Formation, and Virulence in Burkholderia pseudomallei. Infection and Immunity, 0, , .	2.2	0